Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Ultragenyx Pharmaceutical Inc. (RARE)
10:06am, Tuesday, 10'th Feb 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic
SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and Dec
New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultrageny
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical
04:30pm, Monday, 09'th Feb 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical I
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
03:30am, Monday, 09'th Feb 2026
LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for v
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
03:25am, Monday, 09'th Feb 2026
LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("U
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit
03:01am, Monday, 09'th Feb 2026
NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc
LEADING EDGE MATERIALS AND ASCENSION EARTH RESOURCES TEAM UP ON HEAVY RARE EARTHS RECOVERY FROM NORRA KÄRR EUDIALYTE
02:30am, Monday, 09'th Feb 2026
LEADING EDGE MATERIALS AND ASCENSION EARTH RESOURCES TEAM UP ON HEAVY RARE EARTHS RECOVERY FROM NORRA KÄRR EUDIALYTE Strategic collaboration aims to assess innovative recovery methods for Heavy Rare
NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutic
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Ultragenyx Investors Who Suffered Losses Exceeding $50,000 To Contact Him Directly To Discuss Their Options If you pur
New class action for Ultragenyx (RARE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/6/2026.
SAN DIEGO, Feb. 07, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and
NEW ORLEANS, Feb. 6, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities
SAN DIEGO--(BUSINESS WIRE)---- $RARE #RARE--Ultragenyx allegedly misled investors about setrusumab's potential Phase 3 study success in reducing fracture rates.
